Gut Lesions Due to Slow-Release KCl Tablets

Stephen M. Weiss; Harold L. Rutenberg; David L. Paskin; Howard A. Zaren; Richard E. Katholi; Peter M. Levitin

doi:10.1056/NEJM197701132960223

Gut Lesions Due to Slow-Release KCl Tablets

Stephen M. Weiss, Harold L. Rutenberg, David L. Paskin, Howard A. Zaren, Richard E. Katholi, Peter M. Levitin

Surgical Oncology

Research output: Contribution to journal › Letter › peer-review

17 Scopus citations

Abstract

To the Editor: Enteric-coated potassium preparations were withdrawn from the United States drug market after an association with acute small-bowel obstruction and ulceration was demonstrated.¹^,² A slow-release formation of potassium chloride (KCl) has recently been introduced (Slow-K, Ciba) that is designed to reduce the rate of solubility of KCl by coating the crystals with an inert, insoluble wax, thereby avoiding high intraluminal concentrations of the compound. Nevertheless, esophageal ulceration has been reported in a patient with an enlarged left atrium who was taking Slow-K,³ and in patients in congestive heart failure with presumably delayed intestinal transit small-bowel ulceration has.

Original language	English (US)
Pages (from-to)	111-112
Number of pages	2
Journal	New England Journal of Medicine
Volume	296
Issue number	2
DOIs	https://doi.org/10.1056/NEJM197701132960223
State	Published - Jan 13 1977

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM197701132960223

Cite this

@article{5df77bf85c7447638fc366f1341076b4,

title = "Gut Lesions Due to Slow-Release KCl Tablets",

abstract = "To the Editor: Enteric-coated potassium preparations were withdrawn from the United States drug market after an association with acute small-bowel obstruction and ulceration was demonstrated.1,2 A slow-release formation of potassium chloride (KCl) has recently been introduced (Slow-K, Ciba) that is designed to reduce the rate of solubility of KCl by coating the crystals with an inert, insoluble wax, thereby avoiding high intraluminal concentrations of the compound. Nevertheless, esophageal ulceration has been reported in a patient with an enlarged left atrium who was taking Slow-K,3 and in patients in congestive heart failure with presumably delayed intestinal transit small-bowel ulceration has.",

author = "Weiss, {Stephen M.} and Rutenberg, {Harold L.} and Paskin, {David L.} and Zaren, {Howard A.} and Katholi, {Richard E.} and Levitin, {Peter M.}",

year = "1977",

month = jan,

day = "13",

doi = "10.1056/NEJM197701132960223",

language = "English (US)",

volume = "296",

pages = "111--112",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "2",

}

TY - JOUR

T1 - Gut Lesions Due to Slow-Release KCl Tablets

AU - Weiss, Stephen M.

AU - Rutenberg, Harold L.

AU - Paskin, David L.

AU - Zaren, Howard A.

AU - Katholi, Richard E.

AU - Levitin, Peter M.

PY - 1977/1/13

Y1 - 1977/1/13

N2 - To the Editor: Enteric-coated potassium preparations were withdrawn from the United States drug market after an association with acute small-bowel obstruction and ulceration was demonstrated.1,2 A slow-release formation of potassium chloride (KCl) has recently been introduced (Slow-K, Ciba) that is designed to reduce the rate of solubility of KCl by coating the crystals with an inert, insoluble wax, thereby avoiding high intraluminal concentrations of the compound. Nevertheless, esophageal ulceration has been reported in a patient with an enlarged left atrium who was taking Slow-K,3 and in patients in congestive heart failure with presumably delayed intestinal transit small-bowel ulceration has.

AB - To the Editor: Enteric-coated potassium preparations were withdrawn from the United States drug market after an association with acute small-bowel obstruction and ulceration was demonstrated.1,2 A slow-release formation of potassium chloride (KCl) has recently been introduced (Slow-K, Ciba) that is designed to reduce the rate of solubility of KCl by coating the crystals with an inert, insoluble wax, thereby avoiding high intraluminal concentrations of the compound. Nevertheless, esophageal ulceration has been reported in a patient with an enlarged left atrium who was taking Slow-K,3 and in patients in congestive heart failure with presumably delayed intestinal transit small-bowel ulceration has.

UR - http://www.scopus.com/inward/record.url?scp=0017601515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017601515&partnerID=8YFLogxK

U2 - 10.1056/NEJM197701132960223

DO - 10.1056/NEJM197701132960223

M3 - Letter

C2 - 830293

AN - SCOPUS:0017601515

SN - 0028-4793

VL - 296

SP - 111

EP - 112

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 2

ER -

Gut Lesions Due to Slow-Release KCl Tablets

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this